Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly Shares Outstanding (Entity) of $1.3 billion for Q1 2026, up 1.44% year-on-year from $1.3 billion in Q1 2025, and up 1.11% on a QoQ basis from $1.3 billion in Q4 2025.
Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Shares Outstanding (Entity) for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 1.44% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 1.44% YoY) and the FY2025 annual result came in at $1.3 billion, up 1.37% from the prior year.
- Shares Outstanding (Entity) climbed to $1.3 billion in Q1 2026 per TEVA's latest filing, from $1.3 billion in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for TEVA reached as high as $1.3 billion in Q1 2026 and fell as low as $1.1 billion in Q2 2022.
- A 5-year average of $1.2 billion and a median of $1.2 billion in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) declined 8.19% — and 2023, when it rose 10.54%.
- Year by year, Shares Outstanding (Entity) stood at $1.2 billion in 2022, then increased by 0.82% to $1.2 billion in 2023, then advanced by 1.06% to $1.2 billion in 2024, then climbed by 1.37% to $1.3 billion in 2025, then increased by 1.11% to $1.3 billion in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.3 billion, $1.3 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 455,871.00 |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Bn |
| Dec 31, 2025 | 1.15 Bn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 1.15 Bn |
| Mar 31, 2025 | 1.14 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.13 Bn |
| Jun 30, 2024 | 1.13 Bn |
| Mar 31, 2024 | 1.12 Bn |
| Dec 31, 2023 | 1.12 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.12 Bn |
| Dec 31, 2022 | 1.11 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.11 Bn |
| Dec 31, 2021 | 1.10 Bn |
| Sep 30, 2021 | 1.10 Bn |
| Jun 30, 2021 | 1.10 Bn |